PHI with Hanot's disease
How does this condition affect your private health insurance?
Hanot-Krankheit, now commonly known as Primary Biliary Cholangitis (PBC), is a chronic autoimmune liver disease. It targets and progressively destroys the small bile ducts within the liver, impeding the flow of bile. This leads to cholestasis, inflammation, and eventually cirrhosis if untreated. Patients often experience fatigue and intense itching (pruritus), though many remain asymptomatic for years. Diagnosis typically involves specific blood tests, especially for anti-mitochondrial antibodies, and sometimes a liver biopsy. The primary treatment, ursodeoxycholic acid, helps slow disease progression, but there is currently no cure. Left untreated, it can result in liver failure.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Symptoms develop insidiously over months to years, often unrecognized initially; diagnosis is typically made after symptoms persist or through routine blood tests.
Duration of Illness (Lifetime)
Chronic and progressive, typically lasting for decades if untreated or managed, potentially leading to liver failure and necessitating transplant.
Cost of Treatment (Initial)
Initial diagnostic work-up (blood tests, imaging, specialist consultation) can range from several hundred to a few thousand USD, followed by ongoing medication costs.
Cost of Treatment (Lifetime)
Significant, potentially tens of thousands to hundreds of thousands USD over a lifetime, including medication (e.g., UDCA), regular monitoring, and potentially liver transplant (which is very costly).
Mortality Rate
Variable; significantly reduced with early diagnosis and effective treatment, often leading to a near-normal life expectancy. Untreated, advanced disease can lead to liver failure with a high probability of death.
Risk of Secondary Damages
High. Includes osteoporosis, malabsorption of fat-soluble vitamins, portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, and increased risk of hepatocellular carcinoma or cholangiocarcinoma.
Probability of Full Recovery
Extremely low. PBC is a chronic, progressive autoimmune disease; treatment aims to slow progression and manage symptoms, not to achieve a complete recovery or cure. Lifelong management is typically required.
Underlying Disease Risk
Increased risk of other autoimmune conditions such as Sjögren's syndrome, rheumatoid arthritis, thyroid disease, and systemic sclerosis.